Market Overview:

The global rapid acting insulin market size reached US$ 7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2027, exhibiting a growth rate (CAGR) of 5.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Rapid acting insulin is a medication used to control glucose levels in patients with diabetes. It is either inhaled or administered into the bloodstream with a syringe, a pre-filled pen, or an insulin pump. It is taken prior to meals and snacks to bring overly high blood glucose to a normal level and surge the level of bolus insulin. At present, new insulin formulations like novel ultra-paid-acting insulins that enhance absorption are considered a suitable option for people who cannot achieve postprandial glycemic targets with other bolus insulins.

Rapid Acting Insulin Market Trends:

Diabetes mellitus (DM) and poorly controlled blood glucose can increase the risk of mortality and severity among patients with coronavirus disease (COVID-19). This represents one of the key factors fueling the need for rapid acting insulins to monitor blood glucose levels. Apart from this, the growing prevalence of type 1 diabetes on account of exposure to viruses and other environmental factors and low levels of vitamin D acts as another factor propelling the demand for rapid acting insulins across the globe. This can also be attributed to the increasing instances of neonatal jaundice in newborns, in confluence with improving diagnostic modalities. In addition to this, as the risk of developing diabetes increases with age, the rising global geriatric population is facilitating the market growth. Furthermore, leading market players are introducing ready-to-use rapid acting insulin kits that are fast, accessible in vials and a pen presentation, and help enhance glycemic control in both adults and children. These players are also focusing on mergers and acquisitions (M&A), which is anticipated to contribute to the development of new-generation product variants.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

• Lispro Insulin
• Aspart Insulin
• Glulisine Insulin
   

Breakup by Indication:

• Type 1 Diabetes
• Type 2 Diabetes
   

Breakup by Distribution Channel:

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Stores
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.

Report Coverage:

Key Questions Answered in This Report:

• How has the global rapid acting insulin market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global rapid acting insulin market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global rapid acting insulin market and who are the key players?
• What is the degree of competition in the industry?